Non-covalent cathepsin K inhibitors for the treatment of osteoporosis

Current Topics in Medicinal Chemistry

Volumn 6, Issue 4, 2006, Pages 355-360

  Kim, Tae Seong ^a   Tasker, Andrew S ^a  

^a AMGEN INC   (United States)

Author keywords

Cathepsin; Inhibitor; Non covalent

Indexed keywords

(4 PIPERIDINYLPHENYL)AMINOETHYLAMIDE DERIVATIVE; ALENDRONIC ACID; ANILINE DERIVATIVE; BALICATIB; CALCITONIN; CATHEPSIN K; CATHEPSIN K INHIBITOR; CYSTEINE PROTEINASE; CYSTEINE PROTEINASE INHIBITOR; ESTROGEN DERIVATIVE; IBANDRONIC ACID; PARATHYROID HORMONE; RALOXIFENE; RELACATIB; RISEDRONIC ACID; UNCLASSIFIED DRUG;

CLINICAL STUDY; CLINICAL TRIAL; DRUG INDUSTRY; DRUG MECHANISM; DRUG POTENCY; DRUG STRUCTURE; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; MOLECULAR MODEL; OSTEOLYSIS; OSTEOPOROSIS; PATENT; PUBLICATION; REVIEW; STRUCTURE ANALYSIS; VALIDATION PROCESS;

CATHEPSINS; CYSTEINE PROTEINASE INHIBITORS; HUMANS; MODELS, MOLECULAR; OSTEOPOROSIS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 33646163936     PISSN: 15680266     EISSN: None     Source Type: Journal    
DOI: 10.2174/156802606776287036     Document Type: Review

References (21)

1. Sato, M.; Grese, T. A.; Dodge, J. A.; Bryant, H. U.; Turner, C. H. Emerging Therapies for the Prevention or Treatment of Postmenopausal Osteoporosis. J. Med. Chem. 1999, 42, 1-24.
2. 2, a Matrix Protein Degrading Cysteine Protease Expressed in Osteoclasts J. Biol. Chem. 1996, 271, 2126-2132.
3. Grabowska, U. B.; Chambers, T. J.; Shiroo, M. Recent Developments in Cathepsin K Inhibitor Design. Curr. Opin. Drug Disco. Dev. 2005, 8, 619-630.
4. Cai, J.; Jamieson, C.; Moir, J.; Rankovic, Z. Cathepsin K Inhibitors, 2000 - 2004. Exp. Opin. Ther. Patents 2005, 15, 33-48.
5. Grey, A.; Reid, I. R.; Emerging and Potential Therapies for osteoporosis Exp. Opin. Investig. Drugs 2005, 14, 265-278
6. Troen, B. R. The Role of Cathepsin K in Normal Bone Resorption. Drug News Perspect. 2004, 17, 19-28.
7. Deaton, D. N.; Kumar, S. Cathepsin K Inhibitors: Their Potential as Anti-osteoporosis Agents. Prog. Med. Chem. 204, 42, 245-375.
8. Zaidi, M.; Troen, B.; Moonga, B. S.; Abe, E. Cathepsin K, Osteoclastic Resorption, and Osteoporosis Therapy. J. Bone Miner. Res. 2001, 16, 1747-1749.
9. Yamashita, D. S.; Dodds, R. A. Cathepsin K and the Design of Inhibitors of Cathepsin K. Curr. Pharm. Des. 2000, 6, 1-24.
10. Leung, D.; Abbenante, G.; Fairlie, D. P. Protease Inhibitors: Current Status and Future Prospects. J. Med. Chem. 2000, 43, 305-341.
11. IDdb web search ref. 581315, 599054.
12. IDdb web search ref. 638027.
13. IDdb web search ref. 550749.
14. Altmann, E.; Renaud, J.; Tintelnot-Blomley, M. Arylaminoethyl Amides as Inhibitors of the Cysteine Protease Cathepsin K- Investigating p1' Substituent. Bioorg. Med. Chem. Lett. 2003, 13, 1997.
15. Altmann, E.; Renaud, J.; Green, J.; Farley, D.; Cutting, B.; Jahnke, W. Arylaminoethyl Amides as Novel Non-Covalent Cathepsin K Inhibitors. J. Med. Chem. 2002, 45, 2352.
16. Kim, T.-S.; Hague, A. B.; Lee, T. I.; Lian, B.; Tegley, C. M.; Wang, X.; Burgess, T. L.; Qian, Y.-X.; Ross, S.; Tagari, P.; Lin, C.-H.; Mayeda, C.; Dao, J.; Jordan, S.; Mohr, C.; Cheetham, J.; Viswanadhan, V.; Tasker, A. S. (4-Piperidinylphenyl)-aminoethyl Amides as a Novel Class of Non-covalent Cathepsin K Inhibitors. Bioorg. Med. Chem. Lett. 2004, 14, 87-90.
17. Sasaki, T.; Kishi, M.; Saito, M.; Tanaka, T.; Higuchi, N.; Kominami, E.; Katunuma, N.; Murachi, T. Inhibitory effect of Di-and Tripeptidyl Aldehydes on Calpains and Cathepsins. J. Enzyme Inhibit. 1990, 3, 195-201.
18. DesJarlais, R. L.; Yamashita, D. S.; Oh, H.-J.; Uzinskas, I. N.; Erhard, K. F.; Allen, A. C.; Haltiwanger, R. C.; Zhao, B.; Smith, W. W.; Abdel-Meguid, S. S.; D'Alessio, K.; Janson, C. A.; McQueney, M. S.; Tomaszek, T. A.; Levy, M. A.; Veber, D. F. Use of X-ray Co-crystal Structures and Molecular Modeling To Design Potent and Selective Non-peptide Inhibitors of Cathepsin K. J. Am. Chem. Soc. 1998, 120, 9114-9115.
19. Burgess, T. L.; Qian, Y.-X.; Kaufman, S.; Ring, B. D.; Van,G.; Capparelli, C.; Kelley, M.; Hsu, H.; Boyle, W. J.; Dunstan, C. R.; Hu, S.; Lacey, D. L. The Ligand for Osteoprotegerin (OPGL) Directly Activates Mature Osteoclasts. J. Cell Biol. 1999, 145, 527-538.
20. Rosen, C.J.; Brown, S. A. A Rational Approach to Evidence Gaps in the Management of Osteoporosis. Am. J. Med. 2005, 118, 1183-1189.
21. Schwarz, E. M.; O'Keefe, R. J.; Xing, L.; Looney, R. J.; Ritchlin, C. T. Receptor Activator of Nuclear kB Ligand and Osteoprotegerin: where are we now and what about future treatment uses? Curr. Opin. Orthop. 2005, 16, 370-375.